2013

• Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2013), Arthritis: Its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Annals of Epidemiology. 23(2), 80-86. [Abstract]
• Wu, B., Chen, K., Shrestha, S., Ong, K., Barter, P., Rye, K. (2013), High Density Lipoproteins Inhibit Vascular Endothelial Inflammation by Increasing 3β-Hydroxysteroid-{Delta}24 Reductase Expression and Inducing Heme Oxygenase-1. Circulation Research. 112(2), 278-288. [Abstract]

2012

• Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012), Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism. 97(12), 4701-4708. [Abstract]
• Barter, P., Rye, K., Beltangady, M., Ports, W., Duggan, W., Boekholdt, S., Demicco, D., Kastelein, J., Shear, C. (2012), Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of Lipid Research. 53(11), 2436-2442. [Abstract]
• Barter, P., Rye, K. (2012), Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research. 53(9), 1755-1766. [Abstract]
• Rye, K., Barter, P. (2012), The inhibition of cholesteryl ester transfer protein: a long and winding road. Journal of Lipid Research. 53(6), 1039-1041. [Abstract]
• Huijgen, R., Boekholdt, S., Arsenault, B., Bao, W., Davaine, J., Tabet, F., Petrides, F., Rye, K., DeMicco, D., Barter, P., Kastelein, J., Lambert, G. (2012), Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. Journal of the American College of Cardiology. 59(20), 1778-1784. [Abstract]
• Nicholls, S., Gordon, A., Johannson, J., Ballantyne, C., Barter, P., Brewer, H., Kastelein, J., Wong, N., Borgman, M., Nissen, S. (2012), ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovascular Drugs and Therapy. 26(2), 181-187. [Abstract]
• Drew, B., Rye, K., Duffy, S., Barter, P., Kingwell, B. (2012), The emerging role of HDL in glucose metabolism. Nature Reviews. Endocrinology. 8(4), 237-245. [Abstract]
• Rye, K., Barter, P. (2012), Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochimica et biophysica acta. 1821(3), 473-480. [Abstract]
• Arsenault, B., Boekholdt, S., Hovingh, G., Hyde, C., DeMicco, D., Chatterjee, A., Barter, P., Deedwania, P., Waters, D., LaRosa, J., Pedersen, T., Kastelein, J. (2012), The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circulation. Cardiovascular Genetics. 5(1), 51-57. [Abstract]
• Wu, B., Chen, K., Barter, P., Rye, K. (2012), Niacin Inhibits Vascular Inflammation via the Induction of Heme Oxygenase-1. Circulation. 125(1), 150-8. [Abstract]
• Tso, C., Rye, K., Barter, P. (2012), Phenotypic and functional changes in blood monocytes following adherence to endothelium. PLoS One. 7(5), e37091. [Abstract]
• Morales-Villegas, E., Moreno-Virgen, G., Barter, P. (2012), CETP pharmacological manipulation transforming human into mouse: Is this still a viable hypothesis?. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry. 12(4), 266-278.

2011

• Nicholls, S., Ballantyne, C., Barter, P., Chapman, M., Erbel, R., Libby, P., Raichlen, J., Uno, K., Borgman, M., Wolski, K., Nissen, S. (2011), Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. The New England journal of medicine. 365(22), 2078-87. [Abstract]
• Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2011), Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis. 219(2), 728-33. [Abstract]
• Barter, P., Rye, K. (2011), Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?. Trends in pharmacological sciences. 32(12), 694-9. [Abstract]
• Barter, P. (2011), Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction. Atherosclerosis. Supplements. 12, 265-266. [Abstract]
• Barter, P. (2011), HDL-C: Role as a risk modifier. Atherosclerosis. Supplements. 12(3), 267-270. [Abstract]
• Chan, J., Chan, S., Deerochanawong, C., Go, R., Lee, K., Ma, R., Pan, C., Sheu, W., Barter, P. (2011), Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know. Diabetes research and clinical practice. 94(1), 1-13. [Abstract]
• Watts, G., Sullivan, D., Poplawski, N., van Bockxmeer, F., Hamilton-Craig, I., Clifton, P., O'Brien, R., Bishop, W., George, P., Barter, P., Bates, T., Burnett, J., Coakley, J., Davidson, P., Emery, J., Martin, A., Farid, W., Freeman, L., Geelhoed, E., Juniper, A., Kidd, A., Kostner, K., Krass, I., Livingston, M., Maxwell, S., O'Leary, P., Owaimrin, A., Redgrave, T., Reid, N., Southwell, L., Suthers, G., Tonkin, A., Towler, S., Trent, R. (2011), Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis. Supplements. 12(2), 221¿263. [Abstract]
• Barter, P., Rye, K., Tardif, J., Waters, D., Boekholdt, S., Breazna, A., Kastelein, J. (2011), Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. Circulation. 124(5), 555-62. [Abstract]
• Di Bartolo, B., Nicholls, S., Bao, S., Rye, K., Heather, A., Barter, P., Bursill, C. (2011), The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis. 217(2), 395-400. [Abstract]
• Reimers, G., Jackson, C., Rickards, J., Chan, P., Cohn, J., Rye, K., Barter, P., Rodgers, K. (2011), Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovascular research. 91(1), 37-44. [Abstract]
• Preiss, D., Seshasai, S., Welsh, P., Murphy, S., Ho, J., Waters, D., DeMicco, D., Barter, P., Cannon, C., Sabatine, M., Braunwald, E., Kastelein, J., de Lemos, J., Blazing, M., Pedersen, T., Tikkanen, M., Sattar, N., Ray, K. (2011), Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 305(24), 2556-2564. [Abstract]
• Nicholls, S., Borgman, M., Nissen, S., Raichlen, J., Ballantyne, C., Barter, P., Chapman, M., Erbel, R., Libby, P. (2011), Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion. 27(6), 1119-1129. [Abstract]
• Tabet, F., Lambert, G., Cuesta Torres, L., Hou, L., Sotirchos, I., Touyz, R., Jenkins, A., Barter, P., Rye, K. (2011), Lipid-free apolipoprotein a-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 31(5), 1192-200. [Abstract]
• Waters, D., Ho, J., DeMicco, D., Breazna, A., Arsenault, B., Wun, C., Kastelein, J., Colhoun, H., Barter, P. (2011), Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. Journal of the American College of Cardiology. 57(14), 1535-1545. [Abstract]
• Barter, P. (2011), The causes and consequences of low levels of high density lipoproteins in patients with diabetes. Diabetes & Metabolism Journal. 35(2), 101-106. [Abstract]
• Arsenault, B., Barter, P., DeMicco, D., Bao, W., Preston, G., LaRosa, J., Grundy, S., Deedwania, P., Greten, H., Wenger, N., Shepherd, J., Waters, D., Kastelein, J. (2011), Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. Journal of the American College of Cardiology. 57(1), 63-69. [Abstract]
• Di Bartolo, B., Vanags, L., Tan, J., Bao, S., Rye, K., Barter, P., Bursill, C. (2011), The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. Lipids in Health and Disease. 10, 224. [Abstract]
• Ong, K., Barter, P., Rye, K. (2011), Response to statin use and serum bilirubin levels. Atherosclerosis. , 392.

2010

• Cannon, C., Shah, S., Dansky, H., Davidson, M., Brinton, E., Gotto, A., Stepanavage, M., Liu, S., Gibbons, P., Ashraf, T., Zafarino, J., Mitchel, Y., Barter, P. (2010), Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. The New England journal of medicine. 363(25), 2406-15. [Abstract]
• Waterworth, D., Ricketts, S., Song, K., Chen, L., Zhao, J., Ripatti, S., Aulchenko, Y., Zhang, W., Yuan, X., Lim, N., Luan, J., Ashford, S., Wheeler, E., Young, E., Hadley, D., Thompson, J., Braund, P., Johnson, T., Struchalin, M., Surakka, I., Luben, R., Khaw, K., Rodwell, S., Loos, R., Boekholdt, S., Inouye, M., Deloukas, P., Elliott, P., Schlessinger, D., Sanna, S., Scuteri, A., Jackson, A., Mohlke, K., Tuomilehto, J., Roberts, R., Stewart, A., Kesäniemi, Y., Mahley, R., Grundy, S., McArdle, W., Cardon, L., Waeber, G., Vollenweider, P., Chambers, J., Boehnke, M., Abecasis, G., Salomaa, V., Järvelin, M., Ruokonen, A., Barroso, I., Epstein, S., Hakonarson, H., Rader, D., Reilly, M., Witteman, J., Hall, A., Samani, N., Strachan, D., Barter, P., van Duijn, C., Kooner, J., Peltonen, L., Wareham, N., McPherson, R., Mooser, V., Sandhu, M. (2010), Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 30(11), 2264-2276. [Abstract]
• Patel, S., Di Bartolo, B., Nakhla, S., Heather, A., Mitchell, T., Jessup, W., Celermajer, D., Barter, P., Rye, K. (2010), Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis. 212(2), 392-7. [Abstract]
• Barter, P. (2010), The Relationship between Cholesteryl Ester Transfer Protein and Cardiovascular Risk. Clinical chemistry. 56(10), 1547-9. [Abstract]
• Bursill, C., Castro, M., Beattie, D., Nakhla, S., van der Vorst, E., Heather, A., Barter, P., Rye, K. (2010), High-Density Lipoproteins Suppress Chemokines and Chemokine Receptors In Vitro and In Vivo. Arteriosclerosis, thrombosis, and vascular biology. 30(9), 1773-8. [Abstract]
• Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Mann, K., Simes, J., Best, J., Hamwood, S., Keech, A. (2010), Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia. 53(9), 1846-1855. [Abstract]
• Fryirs, M., Barter, P., Appavoo, M., Tuch, B., Tabet, F., Heather, A., Rye, K. (2010), Effects of High-Density Lipoproteins on Pancreatic {beta}-Cell Insulin Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology. 30(8), 1642-1648. [Abstract]
• Barter, P., Brandrup-Wognsen, G., Palmer, M., Nicholls, S. (2010), Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. Journal of Lipid Research. 51(6), 1546-1553. [Abstract]
• Wu, B., Yan, L., Charlton, F., Witting, P., Barter, P., Rye, K. (2010), Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arteriosclerosis, Thrombosis, and Vascular Biology. 30(5), 968-975. [Abstract]
• Nobécourt, E., Tabet, F., Lambert, G., Puranik, R., Bao, S., Yan, L., Davies, M., Brown, B., Jenkins, A., Dusting, G., Bonnet, D., Curtiss, L., Barter, P., Rye, K. (2010), Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology. 30(4), 766-772. [Abstract]
• Tabet, F., Remaley, A., Segaliny, A., Millet, J., Yan, L., Nakhla, S., Barter, P., Rye, K., Lambert, G. (2010), The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro. Arteriosclerosis, thrombosis, and vascular biology. 30(2), 246-52. [Abstract]
• Laurila, P., Naukkarinen, J., Kristiansson, K., Ripatti, S., Kauttu, T., Silander, K., Salomaa, V., Perola, M., Karhunen, P., Barter, P., Ehnholm, C., Peltonen, L. (2010), Genetic Association and Interaction Analysis of USF1 and APOA5 on Lipid Levels and Atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 30(2), 346-52. [Abstract]
• Nicholls, S., Brandrup-Wognsen, G., Palmer, M., Barter, P. (2010), Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). The American Journal of Cardiology. 105(1), 69-76. [Abstract]

2009

• Barter, P. (2009), Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. The American Journal of Cardiology. 104(10 Suppl), 10E-15E. [Abstract]
• Chirovsky, D., Fedirko, V., Cui, Y., Sazonov, V., Barter, P. (2009), Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 16(4), 404-23. [Abstract]
• Peshavariya, H., Dusting, G., Di Bartolo, B., Rye, K., Barter, P., Jiang, F. (2009), Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free radical research. 43(8), 772-82. [Abstract]
• Patel, S., Puranik, R., Nakhla, S., Lundman, P., Stocker, R., Wang, X., Lambert, G., Rye, K., Barter, P., Nicholls, S., Celermajer, D. (2009), Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis. 204(0), 424-8. [Abstract]
• Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009), Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arteriosclerosis, thrombosis, and vascular biology. 29(6), 950-955. [Abstract]
• Fryirs, M., Barter, P., Rye, K. (2009), Cholesterol metabolism and pancreatic beta-cell function. Current Opinion in Lipidology. 20(3), 159-164. [Abstract]
• McGrath, K., Li, X., Puranik, R., Liong, E., Tan, J., Dy, V., DiBartolo, B., Barter, P., Rye, K., Heather, A. (2009), Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arteriosclerosis, thrombosis, and vascular biology. 29(6), 877-882. [Abstract]
• Rye, K., Bursill, C., Lambert, G., Tabet, F., Barter, P. (2009), The metabolism and anti-atherogenic properties of HDL. Journal of Lipid Research. 50(Suppl 1), S195-S200. [Abstract]
• Ling, H., Waterworth, D., Stirnadel, H., Pollin, T., Barter, P., Kesäniemi, Y., Mahley, R., McPherson, R., Waeber, G., Bersot, T., Cohen, J., Grundy, S., Mooser, V., Mitchell, B. (2009), Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity. 17(4), 737-744. [Abstract]
• Patel, S., Drew, B., Nakhla, S., Duffy, S., Murphy, A., Barter, P., Rye, K., Chin-Dusting, J., Hoang, A., Sviridov, D., Celermajer, D., Kingwell, B. (2009), Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. Journal of the American College of Cardiology. 53(11), 962-971. [Abstract]
• Barter, P. (2009), Evolving Targets of Therapy. In: Clinical Lipidology: A Companion to Braunwald's Heart Disease. (pp.387-395).United Kingdom: Saunders.
• Barter, P., Rye, K. (2009), High-density lipoprotein as a therapeutic target. In: Therepeutic Strategies in Lipid Disorders. (pp.29-42).United Kingdom: Clinical Publishing Services.

2008

• Rye, K., Barter, P. (2008), Antiinflammatory Actions of HDL: A New Insight. Arteriosclerosis, Thrombosis, and Vascular Biology. 28(11), 1890-1891. [Abstract]
• Barter, P., Ginsberg, H. (2008), Effectiveness of combined statin plus omega-3 Fatty Acid therapy for mixed dyslipidemia. The American journal of cardiology. 102(8), 1040-1045. [Abstract]
• Kastelein, J., van der Steeg, W., Holme, I., Gaffney, M., Cater, N., Barter, P., Deedwania, P., Olsson, A., Boekholdt, S., Demicco, D., Szarek, M., Larosa, J., Pedersen, T., Grundy, S. (2008), Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation. 117(23), 3002-9. [Abstract]
• Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008), Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical chemistry. 54(6), 1038-1045. [Abstract]
• Nobécourt, E., Zeng, J., Davies, M., Brown, B., Yadav, S., Barter, P., Rye, K. (2008), Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia. 51(6), 1008-1017. [Abstract]
• Shah, S., Waters, D., Barter, P., Kastelein, J., Shepherd, J., Wenger, N., DeMicco, D., Breazna, A., LaRosa, J. (2008), Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology. 51(20), 1938-43. [Abstract]
• Stirnadel, H., Lin, X., Ling, H., Song, K., Barter, P., Kesäniemi, Y., Mahley, R., McPherson, R., Waeber, G., Bersot, T., Cohen, J., Grundy, S., Mitchell, B., Mooser, V., Waterworth, D. (2008), Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study. Atherosclerosis. 197(2), 868-76. [Abstract]
• Sandhu, M., Waterworth, D., Debenham, S., Wheeler, E., Papadakis, K., Zhao, J., Song, K., Yuan, X., Johnson, T., Ashford, S., Inouye, M., Luben, R., Sims, M., Hadley, D., McArdle, W., Barter, P., Kesäniemi, Y., Mahley, R., McPherson, R., Grundy, S., Bingham, S., Khaw, K., Loos, R., Waeber, G., Barroso, I., Strachan, D., Deloukas, P., Vollenweider, P., Wareham, N., Mooser, V. (2008), LDL-cholesterol concentrations: a genome-wide association study. Lancet. 371(9611), 483-91. [Abstract]
• Homer, V., Marais, A., Charlton, F., Laurie, A., Hurndell, N., Scott, R., Mangili, F., Sullivan, D., Barter, P., Rye, K., George, P., Lambert, G. (2008), Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis. 196(2), 659-666. [Abstract]
• Settasatian, N., Barter, P., Rye, K. (2008), Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. Journal of Lipid Research. 49(1), 115-126. [Abstract]
• Puranik, R., Bao, S., Nobecourt, E., Nicholls, S., Dusting, G., Barter, P., Celermajer, D., Rye, K. (2008), Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis. 196(0), 240-7. [Abstract]
• Barter, P., Rye, K. (2008), Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?. Arteriosclerosis, thrombosis, and vascular biology. 28(0), 39-46. [Abstract]

2007

• Barter, P., Caulfield, M., Eriksson, M., Grundy, S., Kastelein, J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J., Waters, D., Shear, C., Revkin, J., Buhr, K., Fisher, M., Tall, A., Brewer, B. (2007), Effects of Torcetrapib in Patients at High Risk for Coronary Events. The New England journal of medicine. 357(21), 2109-22. [Abstract]
• Barter, P., Puranik, R., Rye, K. (2007), New Insights Into the Role of HDL as an Anti-inflammatory Agent in the Prevention of Cardiovascular Disease. Current cardiology reports. 9(6), 493-498. [Abstract]
• Balkau, B., Deanfield, J., Després, J., Bassand, J., Fox, K., Smith, S., Barter, P., Tan, C., Van Gaal, L., Wittchen, H., Massien, C., Haffner, S. (2007), International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation. 116(17), 1942-51. [Abstract]
• Barter, P., Gotto, A., LaRosa, J., Maroni, J., Szarek, M., Grundy, S., Kastelein, J., Bittner, V., Fruchart, J. (2007), HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. The New England journal of medicine. 357(13), 1301-1310. [Abstract]
• Skropeta, D., Settasatian, C., McMahon, M., Shearston, K., Caiazza, D., McGrath, K., Jin, W., Rader, D., Barter, P., Rye, K. (2007), N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins. Journal of lipid research. 48(9), 2047-2057. [Abstract]
• Barter, P., McPherson, Y., Song, K., Kesäniemi, Y., Mahley, R., Waeber, G., Bersot, T., Mooser, V., Waterworth, D., Grundy, S. (2007), Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. The Journal of clinical endocrinology and metabolism. 92(6), 2041-2045. [Abstract]
• Barter, P., Shear, C. (2007), Aggressive management of obesity in children and young adults: the known challenges and potential opportunities. Clinical pharmacology and therapeutics. 81(5), 627-30. [Abstract]
• Kastelein, J., van Leuven, S., Burgess, L., Evans, G., Kuivenhoven, J., Barter, P., Revkin, J., Grobbee, D., Riley, W., Shear, C., Duggan, W., Bots, M. (2007), Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. The New England journal of medicine. 356(16), 1620-30. [Abstract]
• Nobecourt, E., Davies, M., Brown, B., Curtiss, L., Bonnet, D., Charlton, F., Januszewski, A., Jenkins, A., Barter, P., Rye, K. (2007), The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia. 50(3), 643-653. [Abstract]
• Rye, K., Barter, P. (2007), HDL structure and metabolism: Its regulation by cell membrane receptors. In: The Year in Lipid Disorders. Volume 1. (pp.93-112).United Kingdom: Clinical Publishing.
• Barter, P., Rye, K. (2007), HDL and Atherosclerosis. In: High Density Lipoproteins: From Basic Biology to Clinical Aspects. (pp.491-505).Germany: Wiley-VCH.